News

Abbott‘s Atrasentan Phase 2 study was a double-blind, dose-ranging, placebo-controlled study of subjects with diabetic nephropathy on stable doses of renin-angiotensin system (RAS) inhibitors for more than 2

Par Pharma began shipping 10mg and 20mg strengths of Zafirlukast tablets on 19 November 2010. Accolate, an oral prescription medicine used to treat asthma, works by blocking substances

Azixa is a novel small molecule that acts as a microtubule destabilising agent, causing an arrest of cell division with subsequent programmed cell death, or apoptosis, in cancer

The PTR-35 is designed for vertical mixing applications including hybridisation reactions, cell growing, homogenisation of biological solutions, prevention of blood coagulation and latex diagnostics. The rotator which is

Compugen said that the analysis of the in silico prediction and selection results for the B7/CD28 protein family, the first of three such families selected for validation activities

The initiation of the study for S*BIO’s SB1317 or TG02 has triggered a payment from S*BIO’s development and commercialisation partner for the program, Tragara Pharmaceuticals. Earlier, in January

Rexahn Pharma said that the patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive

The lead product associated with the arrangement is ARC19499, a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I clinical trial in the UK. Baxter said that ARC19499

Medgenics has signed a preclinical development and option agreement with the international biopharmaceutical company worth up to $7m in payments that included funding for preclinical development of Medgenics’